ATAP Advocates
Taking a Stand For Patients


Page 2

ATAP Logo Final (2).png


ATAP Submits CMS Part D Rule Comments

ATAP urges CMS to adopt a policy requiring sponsors to include all price concessions at the point of sale for Medicare beneficiaries. 



Florida bill would help prevent drug bait and switch

By Dr. Robert Levin, President of the Florida Society of Rheumatology

Mary is a 45-year-old patient in my practice with severe rheumatoid arthritis. She was incapacitated. Her illness prevented her from working, and also made it difficult to dress, cook, do housework and other everyday tasks that most of us take for granted.


ATAP Chair Dr. Levin Testifies Before Florida House Subcommittee on PBMS

On December 6, ATAP Chair Dr. Robert Levin testified before the Florida House Health and Innovation Subcommittee on the impact deceptive PBM practices have on patient care. “I went to medical school… I know what the patient has and what’s best for my patient. Unfortunately, the decision-making of what prescriptions are available for our patients has been taken out of my hands,” he said. “The patients are expecting that I’m looking out for them…and [I’m] not having some third-party looking over my shoulder telling me what to do.”


ATAP Sends Letter to House Committee on Energy and Commerce Subcommittee on Health regarding PBMs

We thank the Subcommittee for scheduling today’s hearing entitled “Examining the Drug Supply Chain.” ATAP was formed on a shared concern that PBMs play an increasingly harmful role in our supply chain.


ATAP Sends Letter to Congress Supporting CMS Pass-Through Policy

We urge Congress to encourage CMS to adopt a policy requiring sponsors to include price concessions at the point of
sale for Medicare beneficiaries.

ATAP Logo Final (2).png


ATAP Responds to Federal Innovation Center Request for Information

In a letter submitted to the Centers for Medicare and Medicaid Services (CMS), the Alliance for Transparent and Affordable Prescriptions (ATAP) urged the agency to address the increasingly harmful role of pharmacy benefit managers (PBMs) in the prescription drug delivery system.